U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07561450) titled 'Demodex Blepharitis in Scleral Lens Wearers' on April 14.
Brief Summary: The purpose of this study will be to see if Xdemvy (lotilaner ophthalmic solution) 0.25% has a positive impact on ocular surface symptoms and PROSE device functionality and performance.
The investigators hypothesize the use of Xdemvy in subjects utilizing PROSE treatment will be well tolerated and that the reduction in Demodex mite load on the eyelid margin will result in reduced ocular surface symptoms and improved PROSE tolerance and functionality.
Study Start Date: April 27
Study Type: INTERVENTIONAL
Condition:
Demodex Blepharitis
Intervention:
DRUG: Xd...